Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

Key Takeaways The FDA authorized an Expanded Access Program for NAI to manage lymphopenia in refractory or relapsed solid tumor patients. ImmunityBio’s Cancer BioShield platform enhances NK and T cell ...

Panelists discuss how leveraging resources such as patient assistance programs, insurance navigators, clinical trial databases, advocacy groups, and oncology support services can help overcome access ...

The Novel Tracer 89Zr-TLX250 Main Discussion Topics: 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX). CAIX is an enzyme expressed on the surface of most clear cell renal cell ...

Currently, several FDA-approved agents treat BCG-unresponsive carcinoma in situ (CIS), with or without papillary disease. Pembrolizumab, a single-agent checkpoint inhibitor, has a complete response ...

Urologists from Cleveland Clinic recently collaborated across borders to perform the world’s first remotely conducted robot–assisted high-intensity focused ultrasound (HIFU) focal therapy procedure ...

There has been an explosion of treatment options in non–muscle invasive bladder cancer (NMIBC) in recent years, with even more coming down the pike. Many of these agents have demonstrated encouraging ...

Key Takeaways Apalutamide showed a significant survival advantage over abiraterone and enzalutamide in mCSPC, with a 26% and 23% reduction in mortality risk, respectively. Real-world data are ...

Elterman noted that the interest in FITs is only going to continue to grow. “We have definitely seen a shift in the idea of being able to really tailor treatments to both the individual and terms of ...

Darolutamide was approved in this indication in the US in June 2025. 2 With this approval, darolutamide became the first androgen receptor inhibitor to be FDA approved for use in patients with mHSPC ...

Physician Summary: Overcoming Challenges in Accessing New Therapies for NMIBC Access to new therapies for non-muscle invasive bladder cancer (NMIBC) presents several challenges, including cost, ...

In this episode of Pearls and Perspectives, host Amy Pearlman, MD, is joined by Joshua R. Gonzalez, MD —a board-certified urologist and sexual medicine specialist based in Los Angeles, California—for ...